Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043860 · ClinicalTrials.gov registry record · Phase 1
Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02043860: Clinical Trial Phase 1 study, sponsored by University of Illinois at Chicago.
NCT02043860 is a Phase 1 study that was terminated before completion, run by University of Illinois at Chicago. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02043860, a Phase 1 study, was terminated before completion, sponsored by University of Illinois at Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
In this phase I trial, patients with multiple myeloma will receive standard high dose melphalan with autologous stem cell rescue. In addition the pre-transplant conditioning will include targeted total marrow irradiation (TMI). This conventional 3+3 phase I trial will increase the dose of TMI until the maximum tolerated dose (MTD) is reached. Initial patients enrolled will receive the lowest possible dose of 3Gy. Maximum dose will be 12Gy.
Primary Outcome
To evaluate progression free survival (PFS) and in patients with multiple myeloma undergoing autologous stem cell transplant using the combination of high dose melphalan and total marrow irradiation.
Interventions
- DRUG Melphalan
- RADIATION Total Marrow Irradiation
- DRUG Filgrastim (G-CSF)
- PROCEDURE Autologous Transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-01-10 |
| Est. Completion | 2016-11-07 |
| Phase | Phase 1 |
Why NCT02043860 stopped before completion
NCT02043860 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which Melphalan is the first listed.
NCT02043860 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02043860 about?
NCT02043860 is a clinical study titled "Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma". In this phase I trial, patients with multiple myeloma will receive standard high dose melphalan with autologous stem cell rescue. In addition the pre-transplant conditioning will include targeted total marrow irradiation (TMI). This conventional 3+3 phase I trial will increase the dose of TMI until ...
What is the current status of trial NCT02043860?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-01-10. Estimated completion is 2016-11-07.
What interventions are being tested in trial NCT02043860?
The interventions under investigation include: Melphalan (DRUG), Total Marrow Irradiation (RADIATION), Filgrastim (G-CSF) (DRUG), Autologous Transplant (PROCEDURE).
Who is sponsoring clinical trial NCT02043860?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02043860's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI